"10.1371_journal.pone.0020351","plos one","2011-06-07T00:00:00Z","Amit Dutt; Alex H Ramos; Peter S Hammerman; Craig Mermel; Jeonghee Cho; Tanaz Sharifnia; Ajit Chande; Kumiko Elisa Tanaka; Nicolas Stransky; Heidi Greulich; Nathanael S Gray; Matthew Meyerson","Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America; Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America; Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Kharghar, Navi Mumbai, India","Conceived and designed the experiments: AD MM. Performed the experiments: KT AC. Provided samples and performed the genomic and bioinformatic analysis: AD AHR CM PH JC NS HG KET. Provided cell lines for assays: KET HG. Provided FGFR irreversible inhibitor compound FIIN-1: NSG. Wrote and edited the AD PH MM.Reviewed the manuscript: AD AHR PH CM JC TS AC KT NS HG NSG MM.","M.M. is a consultant to Novartis and receives research support from Novartis, receives research support from Genentech, and is a founding advisor and consultant, and an equity holder in Foundation Medicine. N.G. laboratory receives sponsored research from Novartis. However, this does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","06","Amit Dutt","AD",12,TRUE,2,2,NA,NA,TRUE,FALSE,FALSE,0,NA,FALSE
